Video
Author(s):
Dr Nelson J. Chao reviews treatment sequencing and speculates on the future of the GVHD treatment landscape.
THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC
CD47 Levels Are Prognostic of Response to Magrolimab Plus Docetaxel in Metastatic NSCLC
Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC
PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC
2 Commerce Drive
Cranbury, NJ 08512